These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 11183901)

  • 1. Overactive bladder significantly affects quality of life.
    Abrams P; Kelleher CJ; Kerr LA; Rogers RG
    Am J Manag Care; 2000 Jul; 6(11 Suppl):S580-90. PubMed ID: 11183901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The overactive bladder: an overview for primary care health providers.
    Wein AJ; Rovner ES
    Int J Fertil Womens Med; 1999; 44(2):56-66. PubMed ID: 10338262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of overactive bladder syndrome on the sexual quality of life in Korean young and middle aged women.
    Kim YH; Seo JT; Yoon H
    Int J Impot Res; 2005; 17(2):158-63. PubMed ID: 15510187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The wet patient: understanding patients with overactive bladder and incontinence.
    Serels S
    Curr Med Res Opin; 2004 Jun; 20(6):791-801. PubMed ID: 15200735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining overactive bladder: epidemiology and burden of disease.
    Tubaro A
    Urology; 2004 Dec; 64(6 Suppl 1):2-6. PubMed ID: 15621220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.
    Brubaker L; Chapple C; Coyne KS; Kopp Z
    Urology; 2006 Aug; 68(2 Suppl):3-8. PubMed ID: 16908335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence of overactive bladder.
    Milsom I; Stewart W; Thüroff J
    Am J Manag Care; 2000 Jul; 6(11 Suppl):S565-73. PubMed ID: 11183899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ).
    Matza LS; Thompson CL; Krasnow J; Brewster-Jordan J; Zyczynski T; Coyne KS
    Neurourol Urodyn; 2005; 24(3):215-25. PubMed ID: 15747340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.
    Coyne KS; Sexton CC; Irwin DE; Kopp ZS; Kelleher CJ; Milsom I
    BJU Int; 2008 Jun; 101(11):1388-95. PubMed ID: 18454794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ["Pathophysiology and treatment of the overactive bladder"].
    Yokoyama O
    Hinyokika Kiyo; 2005 Sep; 51(9):599-601. PubMed ID: 16229372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment.
    Palleschi G; Pastore AL; Stocchi F; Bova G; Inghilleri M; Sigala S; Carbone A
    Clin Neuropharmacol; 2006; 29(4):220-9. PubMed ID: 16855424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The overactive bladder and quality of life.
    Epstein LB; Goldberg RP
    Int J Fertil Womens Med; 2005; 50(1):30-6. PubMed ID: 15971719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the effect of overactive bladder symptoms on woman's quality of life during and after first pregnancy?
    Van Brummen HJ; Bruinse HW; Van de Pol G; Heintz AP; Van der Vaart CH
    BJU Int; 2006 Feb; 97(2):296-300. PubMed ID: 16430633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit.
    Marschall-Kehrel D; Roberts RG; Brubaker L
    Urology; 2006 Aug; 68(2 Suppl):29-37. PubMed ID: 16908338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire.
    Piault E; Evans CJ; Espindle D; Kopp Z; Brubaker L; Abrams P
    Neurourol Urodyn; 2008; 27(3):179-90. PubMed ID: 17565727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and burden of overactive bladder in the United States.
    Stewart WF; Van Rooyen JB; Cundiff GW; Abrams P; Herzog AR; Corey R; Hunt TL; Wein AJ
    World J Urol; 2003 May; 20(6):327-36. PubMed ID: 12811491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An epidemiological survey of overactive bladder symptoms in Japan.
    Homma Y; Yamaguchi O; Hayashi K;
    BJU Int; 2005 Dec; 96(9):1314-8. PubMed ID: 16287452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.